Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience

Table 3 Serious adverse events (SAE) during and after chemosaturation with percutaneous hepatic perfusion per patient

per patient	grade 1		grade 2		grade 1/2^a		grade 3		grade 4		grade 3/4
Anemia	6	21%	7	25%	13	46%	3	11%	0	0%	3	11%
leukopenia	9	32%	3	11%	12	43%	4	14%	0	0%	4	14%
Thrombocytopenia	9	32%	0	0%	9	32%	4	14%	0	0%	4	14%
Liver toxicity	10	36%	0	0%	10	36%	0	0%	0	0%	0	0%
Nephrotoxicity	2	7%	0	0%	2	7%	0	0%	0	0%	0	0%
Vascular compl./bleeding	2	7%	0	0%	2	7%	0	0%	0	0%	0	0%
Nausea/vomiting	2	7%	11	39%	13	46%	0	0%	0	0%	0	0%
Cardiovascular	0	0%	0	0%	0	0%	0	0%	1	4%	1	4%
Infection/inflammation	5	18%	0	0%	5	18%	0	0%	0	0%	0	0%
Capillary leak	0	0%	1	4%	1	4%	0	0%	0	0%	0	0%

Of Note: Grading of SAE was based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (2017). ^aCombined number of grade 1 and grade 2 SAEs or grade 3 and grade 4 SAEs, respectively. This table takes into account that several patients received more than one Chemosaturation with percutaneous hepatic perfusion

ISSN: 1470-7330